Introduction
Prostate cancer is one of the leading causes of death among men in the United States. Close to 30 000 men will die from the disease in the United States in 2004 (Jemal et al., 2004) . During its initial stages, prostate cancer growth is dependent on AR signaling triggered by DHT, a metabolically active androgen subproduct (Denmeade and Isaacs, 2002; Feldman and Feldman, 2001) . Therefore, besides radical prostatectomy and definitive radiotherapy in localized prostate cancer, the main treatment for advanced prostate cancer is androgen ablation. Androgen blockade usually decreases the volume of the primary and metastatic lesions by inducing apoptosis (Kyprianou et al., 1990) . Despite the initial response to antiandrogen therapy, the tumors recur in an androgen-independent form that is unresponsive to additional androgen withdrawal and chemotherapy, and in many cases, culminate in the death of the patients (Isaacs, 1999; Oh and Kantoff, 1998) . Thus, it is an important challenge to develop effective therapies and preventives for androgen-independent prostate cancer (AIPC). Consequently, understanding the molecular mechanisms of progression to androgen independence is the first step in this process.
Two main potential mechanisms have been proposed for explaining the development of AIPC. The first is hypersensitive pathway, based on an increase of androgen receptor (AR) signaling during the development of androgen-independent tumors. This increased signaling may be caused by AR amplifications rendering AR sensitive to very low levels of dihydrotestosterone (DHT), by AR mutations allowing inappropriate activation by various nonandrogen steroids and androgen antagonists, or by AR signaling induction in a ligand-independent manner, such as activation by Her/ 2neu (Koivisto et al., 1997; Craft et al., 1999; Taplin et al., 1999; Marcelli et al., 2000; Zhao et al., 2000; Feldman and Feldman, 2001 ). The second mechanism for AIPC is based on the induction of a positive growth signal independent of AR that can overcome the apoptosis induced by androgen depletion, thus establishing a bypass pathway (Ruijter et al., 1999; Feldman and Feldman, 2001) . When crucial survival pathways (such as androgen/AR signaling) are targeted by therapy, there might be selection for mutations that upregulate parallel pathways that can provide a substitute survival signal. In prostate cancer patients being treated with androgen ablation, blocking the apoptosis signal would be one such pathway for tumor cell survival.
Survivin is a bypass candidate gene that can block apoptosis. Survivin has been cloned and characterized as an important member of the inhibitor of apoptosis (IAP) family (Ambrosini et al., 1997) . Specifically, its antiapoptotic function seems to be related to an ability to directly/indirectly inhibit caspases (Altieri, 2001) . Expression of Survivin is regulated in a highly cell cycledependent manner, with a robust expression in the G 2 /M phase (Li and Altieri, 1999) . During this phase, Survivin associates with and is phosphorylated by p34cdc2 on Thr34 (O'Connor et al., 2002) . Such a phosphorylated form seems to be responsible for the antiapoptotic function of the protein. Survivin is not normally expressed in the secretory epithelial cells of the prostate, but is strongly expressed in prostate cancer cells (McEleny et al., 2002) . Furthermore, Survivin has been associated with the established features of biologically aggressive prostate carcinoma, such as higher Gleason scores and metastases to regional lymph nodes (Kishi et al., 2004; Shariat et al., 2004) . In the present report, we describe the role of Survivin in mediating resistance to antiandrogen therapy and the targeting of Survivin as a strategy to enhance sensitivity to androgen blockade in prostate cancer in vitro and in vivo. We also describe the contribution of IGF-1 receptor (IGFR1) pathway in mediating resistance to antiandrogen therapy via Survivin upregulation.
Results
Survivin's role in mediating resistance to antiandrogen therapy in prostate cancer
It was determined that all three prostate cancer cell lines LNCaP, PC-3, and DU-145 demonstrated strong expression of Survivin under physiologic conditions, whereas normal prostatic epithelium has no detectable Survivin expression (Figure 1a) . To address the role of Survivin in hormone therapy, it is necessary to elucidate Survivin expression upon androgen stimulation vs androgen blockade. It was reported that the LNCaP cell line, which is derived from metastases to the supraclavicular lymph node, displays a bell-shaped growth curve in response to increasing dose of DHT in culture (Horoszewicz et al., 1983; Lee et al., 1995; Kim et al., 1996) . Low-dose DHT (10 À9 M) results in an increase in cell proliferation, whereas high doses (>10 À7 M) results in growth arrest. A dose of 2-5 nM DHT, therefore, was used in this study. As Figure 1b demonstrates, treatment with exogenous DHT at a 2-5 nM concentration for 72 h in serum-free media suppressed apoptosis in LNCaP cells as reflected by suppression of cleaved caspase 3 levels. Concomitantly, treatment with DHT in this setting was associated with upregulation in the expression of Survivin. Interestingly, DHT did not upregulate other IAP family members (data not shown). The ability of exogenous androgens to upregulate the expression of Survivin may contribute to the protective effect of androgen toward apoptosis in the androgen-responsive LNCaP cell line. To test this hypothesis, we investigated the relationship of Survivin status with sensitivity to the antiandrogen, Flutamide, in androgen-sensitive LNCaP cells. It was determined that administration of Flutamide significantly decreased Survivin expression levels ( Figure 2a ). There was found to be no such effect of Flutamide on androgenindependent DU-145 and PC-3 cells, however, nor was Flutamide found to have any measurable antitumor effect on these androgen-independent cells. Figure 2b demonstrates the efficient downregulation of phosphoSurvivin upon infection with pAd-S(T34A) and upregulation of phospho-Survivin upon infection with pAd-S(WT), indicating effective technical manipulation of Survivin using our constructs. As shown in Figure 2c , Flutamide treatment was found to significantly increase apoptosis compared to untreated LNCaP cells (Flutamide þ pAd-(Empty) arm vs pAd-(Empty) arm). However, upon Survivin inactivation using adenoviral vectors containing dominant-negative Survivin pAd-S(T34A) combined with Flutamide administration, LNCaP cells were found to have doubled their peak apoptotic index compared to Flutamide administration alone (Flutamide þ pAd-S(T34A) arm vs Flutamide þ pAd-(Empty) arm). Conversely, overexpression of wildtype Survivin with pAd-S(WT) was found to significantly reduce the peak apoptotic index compared to Flutamide administration alone (Flutamide þ pAd-S(WT) arm vs Flutamide þ pAd-(Empty) arm). Of note, the peak apoptosis index of LNCaP cells expressing dominant-negative Survivin (T34A) without Flutamide treatment was 45%. Figure 2d demonstrates that treatment arms with relatively high apoptotic levels had low levels of cell viability and vice versa, essentially Survivin mediates resistance to antiandrogen M Zhang et al confirming our results performed in Figure 2c in a different manner. Therefore, the experiments illustrated in Figure 2c and d clearly demonstrate that Survivin can mediate resistance to antiandrogen therapy in vitro.
In vivo confirmation of these findings was made by androgen ablation in LNCaP xenografts. These xenografts were treated by pAd-(Empty), pAd-S(WT), or pAd-S(T34A) in the presence of Flutamide treatment. Figure 2e and f demonstrate that there were more viable cells in the tumors treated by pAd-S(WT) þ Flutamide than the pAd-(Empty) þ Flutamide group. In contrast, there were significantly fewer viable cells in the tumors treated by pAd-S(T34A) þ Flutamide. Figure 2g demonstrates that this reduced tumor cell viability in the pAd-S(T34A) þ Flutamide treatment arm was also reflected by reduced overall tumor volumes compared to the other treatment arms. This provided further evidence that Survivin mediates resistance to antiandrogen therapy and that antagonism of Survivin enhances hormone response in prostate cancer.
AR-independent regulation of Survivin via the IGFR1/AKT signaling axis
As the PC-3 and DU-145 cell lines also demonstrated strong expression of Survivin, despite not having functional AR, we examined other AR-independent mechanisms of Survivin regulation and whether constitutive activation of these pathways could contribute to resistance to antiandrogen therapy. Given the previously reported relationship between AKT and Survivin (Papapetropoulos et al., 2000; Fukuda et al., 2002; Tran et al., 2002; Ling et al., 2004) , we initially investigated whether androgen-dependent upregulation of Survivin was dependent on AKT. We inactivated AKT using infection with an adenoviral construct containing a kinase-deficient, or dominant-negative isoform of AKT. Figure 3 demonstrates that androgen stimulation with exogenous DHT results in Survivin expression at all phases of the cell cycle in LNCaP cells. However, upon inhibition of AKT with the pAd-AKT-KD construct, Survivin was only expressed in G 2 /M phase of the cell cycle upon DHT stimulation. Given these observations, we hypothesized that Survivin was under the regulation of AKT and that upstream pathways that normally serve to activate AKT can modulate Survivin expression and, hence, resistance to antiandrogen therapies. We examined the possible roles of such growth factors such as IGFs, epidermal growth factor (EGF), hepatocyte growth factor (HGF), and platelet-derived growth factor (PDGF) in upregulating Survivin expression in our panel of prostate cancer cell lines. We found that IGF-1, which was found to be the most potent activator of AKT, as measured by phospho-AKT levels (Dudek et al., 1997; Kulik et al., 1997; Remacle-Bonnet et al., 2000) , was also a potent upregulator of Survivin expression in all the three cell lines cultured in serum-free conditions (Figure 4a) . Curiously, none of the other growth factors were found to appreciably regulate Survivin expression (Figure 4c ). In the presence of exogenous IGF-1 under serum-free conditions, all the three cell lines were found to have Survivin expression in all the three phases of the cell cycle, which was not the case in the absence of exogenous IGF-1 (Figure 4b ). Given these findings that IGF-1 stimulation could upregulate Survivin expression, much like androgen stimulation, we further hypothesized that IGFR1 activation could lead to resistance against antiandrogens. To test this hypothesis, we treated LNCaP cells with Flutamide in the presence or absence of exogenous IGF-1 (Figure 5a ). It was determined that exogenous IGF-1 significantly suppressed Flutamide-induced apoptosis in LNCaP cells (Flutamide þ pAd-(Empty) þ IGF-1 arm vs Flutamide þ pAd-(Empty) arm). However, LNCaP cells expressing dominant-negative Survivin (T34A) demonstrated a significant increase in peak apoptosis levels upon Flutamide administration compared to LNCaP cells expressing wild-type Survivin treated by Flutamide (Flutamide þ pAd-S(T34A) þ IGF-1 arm vs Figure 3 Cell cycle arrest was induced using mimosine (at G1), thymidine (at S), and nocodazole (at G 2 /M), followed by Western blot demonstrating that treatment with 5 nM DHT for 72 h induced pan-cell cycle expression of Survivin in LNCaP cells. However, upon blockade of AKT signaling using a dominant-negative mutant AKT-KD, Survivin was only expressed in the G 2 /M phase of the cell cycle upon DHT stimulation Flutamide þ pAd-(Empty) þ IGF-1 arm). This suggests in vitro that Survivin can, indeed, mediate resistance to antiandrogenic agents. To determine whether inhibition of IGFR1 can restore sensitivity to antiandrogen, LNCaP cells were co-treated with Flutamide and AG1024, a known inhibitor of IGFR1 (Parrizas et al., 1997) (Figure 5b ). It was determined that, indeed, there was a significant reduction in cellular viability in the arm treated by a combination of Flutamide and AG1024 compared to the arm treated by Flutamide alone (Flutamide þ pAd-(Empty) þ AG1024 arm vs Flutamide þ pAd-(Empty) arm). However, this effect was overcome when LNCaP cells were forced to overexpress Survivin (Flutamide þ pAd-S(WT) þ AG1024 arm), supporting the direct role of Survivin in IGFR1-mediated resistance to Flutamide. As would be expected, direct inhibition of Survivin by pAd-S(T34A) alone had a potent antitumor effect, which was equivalent whether in the presence or absence of these two inhibitors, indicating that Survivin upregulation via AR and IGFR1 may be critical in the ability of these two respective pathways in enhancing tumor cell survival. It is also worth noting that the difference in cell viability between the Flutamide þ pAd-(Empty) þ AG1024 and the Flutamide þ pAd-S(T34A) þ AG1024 arms was rather small, indicating that simultaneous inhibition of AR and IGFR1 pathways may represent an alternative strategy to the direct inhibition of Survivin, which appears as effective as the latter. Further, these results were mirrored in vivo using LNCaP xenografts. It was determined that both cell viability (Figure 5c ) and tumor volumes (Figure 5d ) were significantly reduced in xenografts treated by a combination of Flutamide and AG1024 vs Flutamide alone. Like the in vitro experiments, this effect was abrogated by overexpressing wild-type Survivin.
Discussion
Progression to androgen independence remains the main obstacle to improving survival for patients with advanced prostate cancer. Despite the general success of antiandrogen therapy, an androgen-refractory status almost invariably develops with time, with an eventually fatal outcome (Isaacs, 1999; Oh and Kantoff, 1998) . Understanding the molecular mechanisms involved in androgen-independent prostate cancer (AIPC) development is critical for the basic understanding of prostate cancer biology, as well as for designing new potential targeted therapy. Several lines of evidence indicate that hormone resistance may, in part, result from increased activity of antiapoptotic pathways or expression of antiapoptotic genes after androgen withdrawal (Ruijter et al., 1999; Feldman and Feldman, 2001) . Given the accumulating evidence that Survivin, a new member of the IAP family, is associated with both cancer progression and drug resistance (Altieri, 2003a, b; Li, 2003) , we hypothesized that Survivin plays a potentially important role in hormone resistance, and that targeting of Survivin may enhance sensitivity to antiandrogen in prostate cancer.
In this study, we show that treatment with DHT results in a decrease in cellular apoptosis with a concomitant increase in Survivin expression. Previous studies demonstrate that androgens are capable of exerting a protective effect in the androgen-sensitive human prostate cancer cell line LNCaP (Limonta et al., 1995; Okamoto et al., 1997; Kassen et al., 2000; Shen et al., 2000; Tsihlias et al., 2000) . Limited studies, however, have focused on the effects of androgen on apoptosis and, in particular, on the mechanisms and pathways involved in androgens conferring survival in this cell line. The ability of androgen to upregulate the expression of Survivin may explain one of the mechanisms whereby androgens increase the apoptotic threshold in the androgen-responsive prostate cancer. Interestingly, we also find that DHT-induced upregulation of Survivin is suppressed by the expression of a dominant-negative mutant of AKT (AKT-KD). It has been reported that activation of the AKT survival pathway can upregulate Survivin expression and inhibition of AKT can block growth factor-mediated induction of Survivin (Papapetropoulos et al., 2000; Fukuda et al., 2002; Tran et al., 2002; Ling et al., 2004) . Our data demonstrate that DHT stimulates Survivin expression in LNCaP cells via an AKT-dependent mechanism. Therefore, strategies of inhibiting AKT activation, such as the use of IGFR1 inhibitors, may prove to be a promising strategy in prostate cancer therapy. Flutamide is a nonsteroidal pure antiandrogen that acts by inhibiting the uptake and/or binding of DHT to the target cell receptor, thus interfering with androgen action (Goldspiel and Kohler, 1990). As expected, treatment with Flutamide is associated with elevated apoptotic indices and decreased Survivin protein levels in LNCaP cells. Our data suggest that overexpression of Survivin is sufficient to induce androgen-independent growth of androgen-dependent cells. Analysis of clinical samples has demonstrated that the expression of Survivin gradually increases from normal prostate tissue, to low-grade primary carcinoma, to high-grade primary carcinoma, and is highest in lymph node metastases (Kishi et al., 2004; Shariat et al., 2004) . This suggests that Survivin may play a role in the development of AIPC. To test this hypothesis, we overexpressed or inactivated Survivin in LNCaP cells through the use of adenoviral vectors containing either wild-type Survivin or a dominant-negative mutant, respectively. Forced overexpression of Survivin promotes resistance to Flutamide in LNCaP cells. Antagonism of Survivin significantly increases Flutamide-induced apoptosis. The association of Survivin with androgen independency was confirmed in vivo.
We have also demonstrated that activation of IGFR1 signaling confers resistance to Flutamide. IGF-1 has well-characterized mitogenic and antiapoptotic effects that are mediated through the IGFR1 (Peruzzi et al., 1999; Baserga et al., 2003) . There is considerable evidence from both laboratory and population studies that IGF-1 signaling is involved in progression of prostate cancer to androgen independency Survivin mediates resistance to antiandrogen M Zhang et al (Djavan et al., 2001) . It has been reported that IGF-1 enables prostate cancer cells to survive in an androgendepleted environment (Nickerson et al., 2001) . It has also been reported that IGFR1 inhibition suppressed prostate cancer cell proliferation (Burfeind et al., 1996) . Our findings further extend the current understanding of IGF-1-mediated cell survival (resistance to androgen blockade). First, IGF-1 upregulates the expression of Survivin via AKT, which is essential for cell survival and resistance to androgen blockade. This event is independent of AR as it occurs indiscriminately in either ARpositive or -negative cell lines. Second, IGF-1 antagonizes Flutamide-induced apoptosis via Survivinmediated mechanism. Inhibition of Survivin either directly or at the level of IGFR1 abrogates IGF-1-mediated hormone resistance. Third, the IGFR1 inhibitor AG1024 enhances sensitivity to Flutamide. However, this effect is abolished in cells overexpressing Survivin, providing further evidence that Survivin is essential to IGF-1-induced resistance to Flutamide. Taken together, upregulation of Survivin via IGFR1/ AKT signaling during androgen blockade may be one of the mechanisms by which prostate cancer cells develop resistance to antiandrogen (Figure 6 ).
To our knowledge, this is the first report to demonstrate that Survivin can mediate resistance to antiandrogen and targeted inhibition of Survivin may enhance sensitivity to androgen ablation in prostate cancer. This finding extends our current vision of the role of Survivin in the conservation of a cell survival pathway during androgen deprivation, and provides a new insight into the mechanisms involved in AIPC development and progression. Our findings also provide a rational basis for the design of combined therapies, including Survivin and IGFR1 inhibitors, to further enhance the responsiveness of prostate cancer cells to androgen ablation therapy.
Materials and methods

Cell culture and reagents
LNCaP, PC-3, DU-145 (human prostate cancer cell lines), and 293 (human embryonic kidney cell line) were obtained from the American Type Culture Collection (ATCC). LNCaP cells were maintained in RPMI 1640 medium supplemented with 10% (v/v) FBS, 2 mM L-glutamine, and 1.0 mM sodium pyruvate at 371C, 95% humidity and 5% CO 2 . PC-3, DU-145, and 293 cells were maintained in DMEM, supplemented with 10% (v/v) FBS and 1% penicillin/streptomycin at 371C, 95% humidity and 5% CO 2 . DHT and Flutamide were obtained from Sigma (St Louis, MO, USA). The tyrphostin AG1024 was purchased from Calbiochem (San Diego, CA, USA). Adenoviral Survivin constructs, including pAd-S(T34A) (dominant-negative form of Survivin) and pAd-S(WT), were provided courtesy of Dr Dario Altieri. The specific involvement of AKT was examined by using a kinase-inactive dominant-negative form of AKT (AKT-KD) kindly provided by Dr A Bellacosa (Fox Chase Cancer Center, Philadelphia, PA, USA).
Cell cycle synchronization
LNCaP, PC-3, and DU-145 cells were treated with 400 mM mimosone (to arrest cells in G 1 ), 2 mM thymidine (to arrest cells in S), or 0.4 mg/ml nocodazole (to arrest cells in G 2 /M) (all from Sigma, St Louis, MO, USA) for 16 h at 371C, or were arrested at the G 1 /S boundary by sequential culture with 2 mM thymidine and 400 mM mimosine.
Adenoviral preparation
The adenoviruses used for this study were provided generously by Dr Dario Altieri and are described fully elsewhere (Mesri et al., 2001) . The pAd-S(T34A) constructs contain a mutant Thr 34 -Ala mutant Survivin cDNA, which has been previously demonstrated to function as a dominant-negative construct. The pAd-S(WT) vector contains the wild-type Survivin cDNA, which can be used to overexpress wild-type Survivin; the pAd-(Empty) contains an empty vector and was used as controls for several experiments. In all, 1 ml of viral supernatant was used to infect 3 Â 10 6 -5 Â 10 6 293 cells. Viruses were harvested at 2-3-day intervals, which was repeated 3-5 times with a total of 5 Â 10 8 packaging cells, and viral particles were purified by CsCl banding. Green fluorescence forming units (GFU) were estimated by serial dilution of the viral stock in transduced 293 cells.
Western blot analysis
Lysates were generated by placing these cells in RIPA lysis buffer (for Survivin) or Chaps Lysis buffer (for cleaved caspase 3). Bradford assays were performed to determine total protein concentrations, which were normalized to 1 mg/ml for all samples. Samples were then prepared in sample buffer and heated to 951C for 5 min. These samples were then run on 16% polyacrylamide gels for Survivin. Protein lysates (15 ml) in sample buffer from each tissue were loaded within each well. Gels were run at a constant current (40 mA) for 3-4 h for maximum separation. Wet transfer was performed for 4 h at constant voltage (40 V) using polyvinylidene difluoride membrane presoaked in methanol. The membrane was blocked in 5% milk in 0.2% TBST. The membrane was then washed in 0.2% TBST Â 3 for 15 min each. The membranes were then incubated overnight with primary antibodies directed at either Survivin (Novus biological, Littleton, CO, USA) or cleaved caspase 3 (Cell Signaling, Cambridge, MA, USA). Subsequently, the membranes were washed in 0.2% TBST Â 3 for Figure 6 Schematic illustrating the role of Survivin in mediating resistance to androgen ablation in prostate cancer. During androgen withdrawal, AR-independent upregulation of Survivin via IGFR1/AKT signaling confers resistance to antiandrogen therapy in prostate cancer cells 15 min each. The membrane was then incubated with secondary antibody for 45 min. Chemiluminescent (Bio-Rad, Hercules, CA, USA) detection was then used to detect expression of Survivin and cleaved caspase 3, respectively. For each gel, positive and negative controls were loaded for Survivin and cleaved caspase 3, respectively. Actin levels served as internal loading controls.
Apoptosis assay
Apoptosis was assayed by detection of membrane externalization of phosphatidylserine with Annexin V-FITC conjugate (Caltag, Burlingame, CA, USA). Both adherent and floating cells were harvested at various intervals after treatment and resuspended in PBS solution. Both adherent and floating cells were harvested at various intervals after treatment and resuspended in PBS solution. Propidium iodide was added to a final concentration of 1 mg/ml. This was analysed using blue light excitation, and green fluorescence of FITC was measured at 530720 nm, and red fluorescence was measured at >600 nm. Cleaved caspase 3 levels were also assessed using Western analysis, as described above.
Trypan blue exclusion assay
After treatment, cells both suspended in the media and attached to the plates were harvested and exposed to 0.4% Trypan blue (Sigma, St Louis, MO, USA) and counted under a light microscope. The percentage viability (unstained cell count/total cell count Â 100%) was calculated.
In vivo study
Nude male mice, 6-week-old, were obtained from Charles River Laboratories, Inc. (Wilmington, MA, USA). 2 Â 10 6 of LNCaP, PC-3, or DU-145 cells were injected into the flanks of the mice and allowed to reach 0.5 cm in size. These xenografts were injected with either pAd-S(T34A), pAd-S(WT), or pAd-(Empty), and injected intraperitoneally with 25 mg/kg of Flutamide, 30 mg of AG1024, or the vehicle once per day for 2 weeks. For local administration of pAd vectors, tumor masses were injected in three different sites with pAd-S(T34A), pAd-S(WT), or pAd-(Empty) at 5 Â 10 8 GFU/site of injection (50 ml). After 7 days, the animals were euthanized and their tumor burdens were excised. Tumor volumes were measured by a caliper and were calculated as follows: volume ¼ width Â length Â height Â 0.5236. The frozen tissue sections were examined for cell viability. All experiments involving mice were approved by the institutional animal care and use committee.
